[Possible effect of E-selectine on structure and function of arterial vessels in patients with metabolic syndrome]

Likars'Ka Sprava
|April 18, 2008
PubMed

Insights

Endothelial cell activation and arterial changes in metabolic syndrome are linked to obesity and dyslipidemia. Carbohydrate metabolism plays a lesser role in these cardiovascular disease risk factors.

Area of Science:

  • Cardiovascular Science
  • Metabolic Disorders
  • Vascular Biology

Background:

  • Endothelial dysfunction and activation are key in atherosclerosis and cardiovascular events.
  • The link between E-selectin, arterial changes, and metabolic syndrome remains unclear.

Purpose of the Study:

  • To investigate the relationship between E-selectin, endothelial activation, and arterial wall modifications in metabolic syndrome patients.
  • To determine the influence of obesity, dyslipidemia, and carbohydrate metabolism on these vascular changes.

Main Methods:

  • Observational study involving patients with metabolic syndrome.
  • Assessment of endothelial cell activation markers.
  • Evaluation of functional and structural arterial vessel changes.
  • Analysis of metabolic parameters including obesity, dyslipidemia, and carbohydrate metabolism.

Main Results:

  • Endothelial cell activation and arterial wall changes are significantly associated with obesity and dyslipidemia.
  • Carbohydrate metabolism disorders show a less pronounced impact on these vascular alterations.
  • E-selectin levels correlate with the observed functional and structural changes.

Conclusions:

  • Obesity and dyslipidemia are primary drivers of endothelial dysfunction and arterial changes in metabolic syndrome.
  • Targeting obesity and dyslipidemia may be crucial for managing vascular complications in metabolic syndrome.
  • Further research is needed to fully elucidate the role of carbohydrate metabolism and E-selectin.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...